ÂÜÀòÂÒÂ×

Daniel Moynihan has extensive work experience in the legal and compliance field. Daniel currently serves as the General Counsel at ONO PHARMA USA, INC. since June 2022. Prior to this, they worked as the Chief Compliance Officer at Spero Therapeutics from January 2022 to May 2022. From April 2020 to December 2021, they held the role of Vice President and Head of US Legal and Compliance at Oncopeptides AB. Before that, they served as the Chief Compliance Officer at Akcea Therapeutics from September 2018 to April 2020. From November 2016 to September 2018, they worked as the Global Compliance Officer - Life Science at MilliporeSigma. Starting in February 2004, they held multiple roles at EMD Serono, including Chief Compliance Officer and Compliance Counsel from September 2010 to October 2016, and Associate General Counsel from February 2004 to August 2010.

Daniel Moynihan attended the College of the Holy Cross from 1984 to 1988, where they earned a Bachelor of Arts degree in Economics. Following this, they pursued their legal studies at The Catholic University of America, Columbus School of Law from 1990 to 1993, obtaining a Juris Doctor (JD) degree.